Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters used in interventional procedures, particularly in catheter-directed thrombolysis (CDT) of large thrombus in patients affected by arterial and venous thromboembolic (A+VTE) conditions.
Watch and learn what we do to help more patients faster.
Welcome to the Thrombolex product line and our innovative approach to A+VTE treatment. Our team of experts are dedicated to bringing a new standard of care to patients with A+VTE conditions. To improve patient care we have created the BASHIR™ Endovascular Catheter line of products.
What We Do
Thrombolex provides an innovative line of endovascular catheters, which feature a unique combination of pharmaco-mechanical, expandable infusion baskets for effective treatment of A+VTE conditions, especially when treating large thrombus.
These products are the first interventional catheters to rapidly create multiple channels so the patient’s own endogenous lytics can flow into the culprit thrombus, enhanced by infused exogenous thrombolytics.
This unique approach should reduce the amount of thrombolytics used and shorten treatment time, benefiting the patient and reducing healthcare costs. Contact us to learn more about this amazing new line of products.
Designed to Enhance Outcomes
BASHIR™ Endovascular Catheters are the first interventional catheters to rapidly create multiple channels so the patient’s own endogenous lytics can flow into the culprit thrombus and immediately begin to dissolve the clot.
Watch to learn about the Thrombolex difference.
First Clinical Trial - Video Overview
Dr. Riyaz Bashir utilizes the BASHIR™ Endovascular Catheter for the first time. Watch his interview with his first in man patient to learn about the outstanding result.
The BASHIR™ Endovascular Catheter's first clinical patient shares his exciting story about his successful outcome.